Consistently with our data, others also observed no or only minor effects when using rituximab as monotherapy in DLBCL cell lines.50 The anti-lymphoma effect of proTAME combined with a novel agent in clinical development in DLBCL and MCL, namely the selective Bcl-2 inhibitor venetoclax, was also tested. The gene discussed is BCL2; the disease is lymphoma.